CRISPR Therapeutics

CRISPR Therapeutics

Focus:

Type: Public Corporation
Founded: 2013
Previous Name: Inception Genomics


We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases
Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics.

Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic.


Leadership
Samarth Kulkarni
CEO


Financial Performance



Funding


Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2014
25M USD
Series A
2015
64M USD
Series B
2015
33M USD
Corporate Equity
2016
Equity
35.0 / 35.0M USD
36M USD
Series B
2016
56M USD
Post-IPO Equity
2020
Equity
2.0 / 2.0M USD
Known Investors
Name
Type
HQ
Other Relevant Investments
Venture Capital
United Kingdom
Corporation
Germany
Corporation
United States
Asset Management
United States
Asset Management
United States
Venture Capital
United States
Venture Capital
United States
Corporate Venture
United States
Venture Capital
United States
Venture Capital
United States
Investment Bank
United States
*More data available at: [CB Insights] [CrunchBase] [PitchBook]

Related
News